Gunderson Dettmer client Akouos, a gene therapy company that focuses on restoring and preserving hearing announced its Series B financing. The company’s Series B financing, led by Pivotal bioVenture Partners totaled $105 million.

In the announcement of the transaction Manny Simons, Ph.D., Akouos’ CEO, founder and president said, “This year is poised to be one of growth for Akouos, and we are delighted to have the support from a world-class syndicate of investors in our Series B financing to advance our current programs and pipeline of potential genetic medicines for hearing loss.”

The Gunderson Dettmer deal teams were led by Timothy Ehrlich and included David Horne, Gabriella Stearns and Christopher Warren. The Akouos team included Joel Diamond and Brendan McCarthy.